

Dung T Le

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3406115/dung-t-le-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

13,411
citations

25
h-index

54
g-index

54
ext. papers

17,978
ext. citations

10.1
avg, IF

6.01
L-index

#	Paper	IF	Citations
50	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015 , 372, 2509-20	59.2	5560
49	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017 , 357, 409-413	41.3	3274
48	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1-10	2.2	786
47	Microsatellite Instability as a Biomarker for PD-1 Blockade. <i>Clinical Cancer Research</i> , 2016 , 22, 813-20	12.9	470
46	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2207-2218	59.2	455
45	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , 2016 , 17, 1590-1598	21.7	450
44	Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1325-33	3.2	398
43	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11-19	2.2	315
42	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2836-2844	2.2	296
41	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019 , 364, 485-491	33.3	228
40	Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. <i>JAMA Neurology</i> , 2016 , 73, 928-33	17.2	194
39	DNA mismatch repair in cancer. <i>Pharmacology & Therapeutics</i> , 2018 , 189, 45-62	13.9	171
38	Cellular vaccine approaches. <i>Cancer Journal (Sudbury, Mass)</i> , 2010 , 16, 304-10	2.2	93
37	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 332-338	2.4	81
36	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships. <i>Journal of Radiation Oncology</i> , 2013 , 2, 413-425	0.7	57
35	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015 , 6, 42334-44	3.3	54
34	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017 , 22, 627-630	5.7	49

33	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2019 , 25, 7024-7034	12.9	48
32	DNA repair defects and implications for immunotherapy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4236-4237	6.4	37
31	An Expanding Role for Immunotherapy in Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 401-410	7.3	36
30	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3546-3555	2.2	32
29	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , 2018 , 24, 6160-6167	12.9	31
28	Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 5250-5259	12.9	29
27	A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 5129-5139	12.9	28
26	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 2019 , 7, 40		28
25	A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. <i>Cancer Medicine</i> , 2020 , 9, 1485-1494	4.8	25
24	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019 , 7, 1574-1579	12.5	21
23	CD8+ Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. <i>International Journal of Cancer</i> , 2011 , 129, 636-47	7.5	20
22	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. <i>Annals of Surgical Oncology</i> , 2018 , 25, 280-289	3.1	20
21	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2016 , 4, 225-33	12.5	19
20	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	18
19	Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. <i>Oncotarget</i> , 2018 , 9, 16427-16436	3.3	15
18	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017 , 6, 1552-1562	4.8	14
17	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. <i>Cancer Cell</i> , 2021 , 39, 973-988	8.9	13
16	Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1278-1286	12.9	11

15	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021 , 11, 1844-1859	24.4	11
14	Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. <i>Cancer Letters</i> , 2021 , 497, 221-228	9.9	7
13	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021 , 151, 137-196	5.9	6
12	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2020 , 11, 1929-1941	3.3	3
11	High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.. <i>Cancer Medicine</i> , 2022 ,	4.8	2
10	A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. <i>Oncotarget</i> , 2017 , 8, 100942-100950	3.3	2
9	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.. <i>Annals of Surgical Oncology</i> , 2022 , 29, 2456.	3.1	1
8	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 486-489	4	0
7	Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-7	3.6	0
6	Patient- versus physician-reported outcomes in patients enrolled in a prospective study involving stereotactic body radiation therapy in unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 84-84	2.2	
5	Stereotactic body radiation therapy and patient-reported quality of life prospectively evaluated in patients with unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 92-92	2.2	
4	Impact of stereotactic body radiation therapy on patient-reported quality of life in patients with unresectable or recurrent pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 413-413	2.2	
3	A prospective study evaluating stereotactic body radiation therapy in unresectable, recurrent, or residual pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 454-454	2.2	
2	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15028-e15028	2.2	
1	Is successful resection following neoadjuvant radiation therapy for borderline resectable pancreatic cancer dependent on improved tumor-vessel relationships?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4057-4057	2.2	